JPMorgan analyst Anupam Rama lowered the firm’s price target on Apellis (APLS) to $36 from $40 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $19 from $24 at Mizuho
- Apellis Pharmaceuticals’ Earnings Call Highlights FDA Approval and Market Challenges
- Apellis price target lowered to $45 from $50 at TD Cowen
- Apellis price target raised to $52 from $50 at Baird
- Apellis price target lowered to $45 from $52 at Citi